Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

PFIZER INC Director's Dealing 2018

Sep 17, 2018

29831_dirs_2018-09-17_5ed4cd95-15c7-45df-b185-5bacc6b898c7.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PFIZER INC (PFE)
CIK: 0000078003
Period of Report: 2018-09-13

Reporting Person: Dolsten Mikael (President R&D)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2018-09-13 Common Stock M 124501.0000 $21.0300 Acquired 177088.0000 Direct
2018-09-13 Common Stock M 57211.0000 $32.2300 Acquired 234299.0000 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2018-09-13 Stock Appreciation Rights $21.0300 M 185185.0000 Disposed 2019-02-23 Common Stock (185185.0000) Direct
2018-09-13 Stock Appreciation Rights $32.2300 M 158662.0000 Disposed 2019-02-27 Common Stock (158662.0000) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 1600.0000 Indirect

Footnotes

F1: Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in our common stock price (20 trading day average ending on the exercise date (Election Price) of $41.96) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the seventh anniversary of grant.

F2: Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in our common stock price (20 trading day average ending on the exercise date (Election Price) of $41.96) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the fifth anniversary of grant.